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Background
A goal of an AIDS vaccine is to prevent acquisition of HIV-
1 infection. The ability of AIDS vaccine candidates to pro-
tect against mucosal infection by heterologous viruses in
non-human primates will help to define mechanisms and
correlates of immune protection relevant to humans.
Methods
Rhesus monkeys were immunized intramuscularly using
a plasmid DNA prime/recombinant Ad5 boost regimen.
Experimental animals received vectors expressing genes
encoding SIVmac239 env and gag/pol, and control ani-
mals received empty vectors. Monkeys were challenged 4
months after their final immunization with a series of 12
weekly intra-rectal exposures of SIVsmE660 in one study,
and SIVmac251 in a second study. The challenge dose for
each virus was titered to achieve ~50% infection per-inoc-
ulation for control animals. Time to acquisition of infec-
tion was monitored by weekly assessment of plasma SIV
RNA levels.
Results
Experimentally vaccinated monkeys were significantly
protected against infection by the heterologous virus,
SIVsmE660 (n = 25 per arm). There was a 50% reduction
in acquisition of infection and a significant increase in
time to infection in vaccinated animals as compared to
the control animals (log-rank test, p = 0.0009). There was
no significant difference in peak viral loads of infected
vaccinated animals compared to infected controls.
Immune correlates of vaccine protection are being evalu-
ated. A similar vaccine regimen revealed no protection
from acquisition of infection when homologous
SIVmac251 was used as the challenge virus, and effects on
viral load seen previously with this virus are under inves-
tigation.
Conclusion
This study demonstrates vaccine protection against
mucosal acquisition of a heterologous, pathogenic SIV
isolate in rhesus monkeys. The absence of protection
against acquisition of another pathogenic SIV isolate illus-
trates the biological variability of primate immunodefi-
ciency viruses. Protection in a heterologous challenge
model will permit definition of immune correlates of pro-
tection and facilitate the development of highly effective
AIDS vaccines.
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